Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Items 101–200 of 796
Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease
Matsuda, H. (2001) · Annals of Nuclear Medicine · doi:10.1007/bf02988596 · Cited by 232
Neuroimaging in Alzheimer disease: an evidence-based review
Kantarci, K., & Jack, C. R. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00025-x · Cited by 229
“Posterior cingulate gyrus hypometabolism and the rate of decline in glucose metabolism on PET, however, are associated with the ApoE genotype in people with normal cognition [81–83].”
BackgroundBiomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Castelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Pitari, G., Ippoliti, R., Cimini, A., & d’Angelo, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00132 · Cited by 208
Brain imaging evidence of preclinical Alzheimer's disease in normal aging
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., & Haan, M. (2006) · Annals of Neurology · doi:10.1002/ana.20799 · Cited by 222
“Glucose metabolism in parietal and posterior cingulate cortex is predictive of the rate of memory decline in ε4-positive individuals with mild memory loss (but not in those without this allele) over 2 years.(15) Functional MRI has shown areas of increased brain activity, presumed due to compensatory mechanisms, in sub…”
BackgroundEarly detection of Alzheimer's disease using PiB and FDG PET
Cohen, A. D., & Klunk, W. E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.001 · Cited by 202
Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT
Matsuda, H. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037218 · Cited by 214
“The observation that a reduction in metabolism in these areas predicts a cognitive decline in presymptomatic people indicates that the pathophysiologic process begins well before even mild or questionable dementia is recognized clinically (39).”
BackgroundNiwa, K., Kazama, K., Younkin, S. G., Carlson, G. A., & Iadecola, C. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0460 · Cited by 218
“…have pronounced morphological abnormalities (Fischer et al., 1990; Kalaria and Hedera, 1995; Kidd, 1964; Scheibel and Duong, 1988; Stewart et al., 1992), CBF and/or CGU are reduced in patients with AD (Jagust et al., 1998; Prohovnik et al., 1988; Reiman et al., 1996; Small et al., 2000).”
BackgroundMeat‐Adaptive Genes and the Evolution of Slower Aging in Humans
Finch, C. E., & Stanford, C. B. (2004) · The Quarterly Review of Biology · doi:10.1086/381662 · Cited by 219
Trivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., Asthana, S., & Johnson, S. C. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-1 · Cited by 209
“Several positron emission tomography (PET) imaging studies have also reported reductions in resting state cerebral metabolic rate of glucose (CMRgl) in the MTL and cortical regions of AD patients and cognitively normal ε4 carriers between the ages of 20 and 65 years [76-82], suggesting different baseline neural activi…”
BackgroundEstrogen- and tamoxifen-associated effects on brain structure and function
Eberling, J. L., Wu, C., Tong-Turnbeaugh, R., & Jagust, W. J. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.08.037 · Cited by 213
“…both positron emission tomography (PET) (Frackowiak et al., 1981; Friedland et al., 1983) and single photon emission computed tomography (SPECT) (Claus et al., 1994; Eberling et al., 1993; Small et al., 2000) have been reported consistently in subjects with AD and subjects at genetic risk for AD.”
InfluentialAPOE ε4 Genotype and Longitudinal Changes in Cerebral Blood Flow in Normal Aging
Thambisetty, M., Beason-Held, L., An, Y., Kraut, M. A., & Resnick, S. M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.913 · Cited by 209
Rogalski, E. J., Gefen, T., Shi, J., Samimi, M., Bigio, E., Weintraub, S., Geula, C., & Mesulam, M.-M. (2013) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_00300 · Cited by 196
“neurological disease, the ε4 allele may be associated with reduced hippocampal volume (Lind, 2006) and decreased cortical metabolism (Small et al., 2000; Reiman et al., 1996).”
BackgroundAging: The Reality: Biomarkers of Aging: From Primitive Organisms to Humans
Butler, R. N., Sprott, R., Warner, H., Bland, J., Feuers, R., Forster, M., Fillit, H., Harman, S. M., Hewitt, M., Hyman, M., et al. (2004) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/59.6.b560 · Cited by 204
“This technology is becoming extremely important in aging research, especially in studies with human participants (42,43).”
BackgroundDickerson, B. C., & Sperling, R. A. (2009) · Behavioural Neurology · doi:10.1155/2009/610392 · Cited by 197
Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: An MRI Study
O'Dwyer, L., Lamberton, F., Matura, S., Tanner, C., Scheibe, M., Miller, J., Rujescu, D., Prvulovic, D., & Hampel, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048895 · Cited by 192
“Brain structure and function have been found to be altered in ApoE4 carriers, both in AD patients [8,9] and in healthy subjects [10–14].”
BackgroundEarly detection of Alzheimer’s disease using neuroimaging
Mosconi, L., Brys, M., Glodzik-Sobanska, L., De Santi, S., Rusinek, H., & de Leon, M. J. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.05.016 · Cited by 187
Differential effects of the APOE genotype on brain function across the lifespan
Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., Wilcock, G. K., Beckmann, C. F., Smith, S. M., Matthews, P. M., & Mackay, C. E. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.009 · Cited by 196
“Moreover, both regional brain volume and resting glucose metabolism [measured with Positron Emission Tomography (PET)] reductions have been observed in ε4-carriers relative to non-carriers in areas affected by AD pathology, such as the posterior cingulate and medial temporal lobe (MTL) (Reiman et al., 1996; Small et a…”
BackgroundMethodResultInfluentialAlzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms
von Bernhardi, R., & Eugenín, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4082 · Cited by 190
“Nondemented ApoE4 patients show a similar regional pattern of hypometabolism before the onset of disease that correlates with changes seen in the AD brain, suggesting that an ApoE-related decrease in brain metabolism could contribute to development of AD (531, 532, 587).”
BackgroundReactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease
Price, B. R., Johnson, L. A., & Norris, C. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101335 · Cited by 177
“This cerebral glucose hypometabolism is a hallmark of AD (Small et al., 2000), and FDG-PET is able to differentiate AD from other types of dementia with a high degree of specificity due to specific regional patterns of signal (Laforce and Rabinovici, 2011).”
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“…4 alleles but without overt AD revealed decreased brain activity, decreased visual attention, and subtle memory impairments in 4 carriers compared with people with other APOE alleles (Caselli et al., 1999; Bookheimer et al., 2000; Greenwood et al., 2000; Small et al., 2000; Reiman et al., 2001).”
BackgroundInfluentialBenussi, A., Cantoni, V., Grassi, M., Brechet, L., Michel, C. M., Datta, A., Thomas, C., Gazzina, S., Cotelli, M. S., Bianchi, M., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26411 · Cited by 163
“Alterations of the DMN have been identi fi ed as responsible of memory impairment 50 – 52 and the precuneus has been described as a key node for memory functioning.”
BackgroundZahs, K. R., & Ashe, K. H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.05.004 · Cited by 175
The hippocampus and depression
Sheline, Y. I., Mittler, B. L., & Mintun, M. A. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00655-7 · Cited by 174
Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., Durham, R., Soares, H., Kimmel, L., Friedman, D., Bergeson, J., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.021 · Cited by 179
Applications of positron emission tomography (PET) in neurology
Tai, Y. F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.028175 · Cited by 165
Effects of a 14-Day Healthy Longevity Lifestyle Program on Cognition and Brain Function
Small, G. W., Silverman, D. H. S., Siddarth, P., Ercoli, L. M., Miller, K. J., Lavretsky, H., Wright, B. C., Bookheimer, S. Y., Barrio, J. R., & Phelps, M. E. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000219279.72210.ca · Cited by 176
“[Fluorine18]fluorodeoxyglucose (FDG) was used to assess regional cerebral metabolism during mental rest as previously described.(34,35) Subjects were scanned in the supine position 40 minutes after injection of 370 MBq FDG in a dimly lit room having low ambient noise with eyes and ears unoccluded.”
MethodSelf-citationOlfactory deficit detected by fMRI in early Alzheimer's disease
Wang, J., Eslinger, P. J., Doty, R. L., Zimmerman, E. K., Grunfeld, R., Sun, X., Meadowcroft, M. D., Connor, J. R., Price, J. L., Smith, M. B., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.018 · Cited by 165
“…or even invalidated as patients become more demented, and fMRI studies employing cognitive stimulation paradigms in even pre-symptomatic AD can be confounded with strong compensatory activation patterns, creating difficulties for data interpretation (Johnson et al., 2000; Small et al., 2000).”
BackgroundMcDonagh, D. L., Mathew, J. P., White, W. D., Phillips-Bute, B., Laskowitz, D. T., Podgoreanu, M. V., & Newman, M. F. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181d31fd7 · Cited by 172
Jiang, Q., Heneka, M., & Landreth, G. E. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00001 · Cited by 174
“[21,22] Alzheimer’s disease,[98-105,111] and PPARγ target genes or regulatory molecules (such as the uncou- 4.”
BackgroundBrain network local interconnectivity loss in aging APOE-4 allele carriers
Brown, J. A., Terashima, K. H., Burggren, A. C., Ercoli, L. M., Miller, K. J., Small, G. W., & Bookheimer, S. Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109038108 · Cited by 169
Self-citationMorton, H., Kshirsagar, S., Orlov, E., Bunquin, L. E., Sawant, N., Boleng, L., George, M., Basu, T., Ramasubramanian, B., Pradeepkiran, J. A., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.013 · Cited by 169
A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease
Kyrtata, N., Emsley, H. C. A., Sparasci, O., Parkes, L. M., & Dickie, B. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.626636 · Cited by 171
“Later studies confirmed these results, building support for regional declines in CMRglu as a hallmark of AD, including in frontal white matter, caudate, thalamus, temporal, and parietal regions (Small et al., 2000; Mosconi et al., 2004, 2007a).”
ResultWestlye, E. T., Lundervold, A., Rootwelt, H., Lundervold, A. J., & Westlye, L. T. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1230-11.2011 · Cited by 171
“APOE 4 is linked to accelerated brain aging and disease (Small et al., 2000; Deary et al., 2002; Wilson et al., 2002; Bertram et al., 2007; Espeseth et al., 2008).”
BackgroundMitochondrial DNA mutations in neurodegeneration
Keogh, M. J., & Chinnery, P. F. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.05.015 · Cited by 161
A framework for computational anatomy
Thompson, P. M., & Toga, A. W. (2002) · Computing and Visualization in Science · doi:10.1007/s00791-002-0084-6 · Cited by 169
chételat, G., Eustache, F., Viader, F., Sayette, V. D. L., Pélerin, A., Mézenge, F., Hannequin, D., Dupuy, B., Baron, J.-C., & Desgranges, B. (2005) · Neurocase · doi:10.1080/13554790490896938 · Cited by 167
“In previous studies, age was consistently found to be positively associated with increased risk of converting to AD (Small et al., 1995; 2000; Devanand et al., 1997; Rubin et al., 1998; Elias et al., 2000; Visser et al., 2000; 2001; Storandt et al., 2002; Tian et al., 2003; Blackwell et al., 2004).”
ResultEffect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women
Cohen, R. M., Small, C., Lalonde, F., Friz, J., & Sunderland, T. (2001) · Neurology · doi:10.1212/wnl.57.12.2223 · Cited by 161
A right hemisphere role in cognitive reserve
Robertson, I. H. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.028 · Cited by 176
Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 151
“Alterations in resting cerebral glucose metabolism in an AD-like pattern have also been shown in participants who are positive for APOE ε4 and/or those with a positive family history of dementia (de Leon et al. 2001, Small et al. 2000).”
BackgroundResultAnatomical Landmark Based Deep Feature Representation for MR Images in Brain Disease Diagnosis
Liu, M., Zhang, J., Nie, D., Yap, P.-T., & Shen, D. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2791863 · Cited by 161
“requiring expert knowledge in practice [16].”
Desgranges, B., Baron, J., Lalevée, C., Giffard, B., Viader, F., de la Sayette, V., & Eustache, F. (2002) · Brain · doi:10.1093/brain/awf097 · Cited by 160
Hypometabolism as a therapeutic target in Alzheimer's disease
Costantini, L. C., Barr, L. J., Vogel, J. L., & Henderson, S. T. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s16 · Cited by 162
Brain structural alterations before mild cognitive impairment
Smith, C. D., Chebrolu, H., Wekstein, D. R., Schmitt, F. A., Jicha, G. A., Cooper, G., & Markesbery, W. R. (2007) · Neurology · doi:10.1212/01.wnl.0000259542.54830.34 · Cited by 161
Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia
Risacher, S., & Saykin, A. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359312 · Cited by 144
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease
Dickerson, B. C., & Sperling, R. A. (2005) · Neurotherapeutics · doi:10.1602/neurorx.2.2.348 · Cited by 167
“Progressive metabolic abnormalities parallel cognitive decline in both older cognitively intact individuals(97) and subjects with mild memory impairment who carry the APOE- 4 allele.(86) In individuals in their fifties without cognitive decline, progressive metabolic decline has been observed in 4 carriers after 2 yea…”
BackgroundMulti-modal imaging predicts memory performance in normal aging and cognitive decline
Walhovd, K. B., Fjell, A. M., Dale, A. M., McEvoy, L. K., Brewer, J., Karow, D. S., Salmon, D. P., & Fennema-Notestine, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.013 · Cited by 158
Fuller, S. L., Steele, M. L., & Münch, G. W. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.08.016 · Cited by 180
Matsuda, H., Kitayama, N., Ohnishi, T., Asada, T., Nakano, S., Sakamoto, S., Imabayashi, E., & Katoh, A. (2002) · PubMed · Cited by 173
Mayeux, R. P., Small, S. A., Tang, M., Tycko, B., & Stern, Y. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00223-8 · Cited by 173
“[54] Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookhei-”
BackgroundJohnson, S. C., Schmitz, T. W., Trivedi, M. A., Ries, M. L., Torgerson, B. M., Carlsson, C. M., Asthana, S., Hermann, B. P., & Sager, M. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0959-06.2006 · Cited by 147
McDonough, I. M., & Nashiro, K. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00409 · Cited by 163
Increased CSF cortisol in AD is a function of APOE genotype
Peskind, E. R., Wilkinson, C. W., Petrie, E. C., Schellenberg, G. D., & Raskind, M. A. (2001) · Neurology · doi:10.1212/wnl.56.8.1094 · Cited by 152
The APOE ɛ4 allele modulates brain white matter integrity in healthy adults
Heise, V, Filippini, N., Ebmeier, K. P., & Mackay, C. E. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.90 · Cited by 152
Cortical Deactivation in Mild Cognitive Impairment: High-Field-Strength Functional MR Imaging
Petrella, J. R., Wang, L., Krishnan, S., Slavin, M. J., Prince, S. E., Tran, T.-T. T., & Doraiswamy, P. M. (2007) · Radiology · doi:10.1148/radiol.2451061847 · Cited by 149
Shoham, S., Bejar, C., Kovalev, E., & Weinstock, M. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.015 · Cited by 167
Freimer, N. B., & Sabatti, C. (2004) · Nature Genetics · doi:10.1038/ng1433 · Cited by 165
Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
Nakamura, A., Cuesta, P., Fernández, A., Arahata, Y., Iwata, K., Kuratsubo, I., Bundo, M., Hattori, H., Sakurai, T., Fukuda, K., et al. (2018) · Brain · doi:10.1093/brain/awy044 · Cited by 151
“…mode network (Buckner et al. , 2008), because amyloid-b first accumulates in areas associated with the default mode network (Mintun et al. , 2006), and glucose hypometabolism in the posterior hub of the default mode network is an established marker for disease progression (Small et al. , 2000).”
BackgroundUshering in the study and treatment of preclinical Alzheimer disease
Langbaum, J. B., Fleisher, A. S., Chen, K., Ayutyanont, N., Lopera, F., Quiroz, Y. T., Caselli, R. J., Tariot, P. N., & Reiman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.107 · Cited by 146
Lameka, K., Farwell, M. D., & Ichise, M. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00011-8 · Cited by 186
Reduced functional brain activity response in cognitively intact apolipoprotein E ε4 carriers
Lind, J., Persson, J., Ingvar, M., Larsson, A., Cruts, M., Van Broeckhoven, C., Adolfsson, R., Bäckman, L., Nilsson, L.-G., Petersson, K. M., et al. (2006) · Brain · doi:10.1093/brain/awl054 · Cited by 148
“Previous studies with PET and functional MRI (fMRI) have indicated alterations in glucose metabolism (Small et al., 1995, 2000; Reiman et al., 1996, 2004) and task-related brain activation patterns (Smith et al., 1999; Bookheimer et al., 2000) in APOE «4 carriers, well before the diagnosis of…”
ResultWolk (2012) · doi:10.1097/wco.0b013e328354ff0a · Cited by 147
Reactive astrocytes give neurons less support: implications for Alzheimer's disease
Steele, M. L., & Robinson, S. R. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.018 · Cited by 162
Current and future uses of neuroimaging for cognitively impaired patients
Small, G. W., Bookheimer, S. Y., Thompson, P. M., Cole, G. M., Huang, S.-C., Kepe, V., & Barrio, J. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70019-x · Cited by 163
Self-citationAlzheimer Disease: Operating Characteristics of PET— A Meta-Analysis
Patwardhan, M. B., McCrory, D. C., Matchar, D. B., Samsa, G. P., & Rutschmann, O. T. (2004) · Radiology · doi:10.1148/radiol.2311021620 · Cited by 137
Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease
Moreira, P. I., Siedlak, S. L., Wang, X., Santos, M. S., Oliveira, C. R., Tabaton, M., Nunomura, A., Szweda, L. I., Aliev, G., Smith, M. A., et al. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000240476.73532.b0 · Cited by 144
“The importance of such changes is highlighted by the fact that reductions in brain metabolism correlate positively with the degree of dementia (12Y14) and that genetically predisposed patients with AD develop changes in brain metabolism before they develop symptoms of the disease (3).”
BackgroundFocal temporoparietal slow activity in Alzheimer’s disease revealed by magnetoencephalography
Fernández, A., Maestú, F., Amo, C., Gil, P., Fehr, T., Wienbruch, C., Rockstroh, B. S., Elbert, T. R., & Ortiz, T. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01366-5 · Cited by 144
“This line of evidence was confirmed in further studies (Jelic and Nordberg 2000; Muller et al 1999; Nagata et al 2000; Small et al 2000).”
BackgroundResultBrain imaging in the study of Alzheimer's disease
Reiman, E. M., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.075 · Cited by 130
“…Press. early-onset AD, and those with higher rates of subsequent cognitive decline) (Kennedy et al., 1995; Langbaum et al., 2010; Mosconi et al., 2006, 2008; Reiman et al., 1996, 2001, 2004, 2005; Rimajova et al., 2008; Scholl et al., 2011; Small et al., 1995, 2000; Villemagne et al., 2009) (Fig.”
BackgroundCortelli, P., Perani, D., Montagna, P., Gallassi, R., Tinuper, P., Federica, P., Avoni, P., Ferrillo, F., Anchisi, D., Moresco, R. M., et al. (2006) · Brain · doi:10.1093/brain/awl003 · Cited by 145
Greenwood, P. M., Sunderland, T., Friz, J. L., & Parasuraman, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11661 · Cited by 133
Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease
Herholz, K. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.136 · Cited by 129
APOE genotype and stress response - a mini review
Dose, J., Huebbe, P., Nebel, A., & Rimbach, G. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0288-2 · Cited by 137
Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B., & Sperling, R. A. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 133
Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease
Yezhuvath, U. S., Uh, J., Cheng, Y., Martin-Cook, K., Weiner, M., Diaz-Arrastia, R., van Osch, M., & Lu, H. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.005 · Cited by 133
Weakly Supervised Deep Learning for Brain Disease Prognosis Using MRI and Incomplete Clinical Scores
Liu, M., Zhang, J., Lian, C., & Shen, D. (2019) · IEEE Transactions on Cybernetics · doi:10.1109/tcyb.2019.2904186 · Cited by 125
“However, this type of representation requires a priori hypothesis on abnormal regions from a structural/functional perspective to define regions in the brain [39], while such a hypothesis may not always hold in practice.”
BackgroundBrain Metabolic Alterations in Alzheimer’s Disease
Ardanaz, C. G., Ramírez, M. J., & Solas, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073785 · Cited by 125
The apolipoprotein E gene, attention, and brain function.
Parasuraman, R., Greenwood, P. M., & Sunderland, T. (2002) · Neuropsychology · doi:10.1037//0894-4105.16.2.254 · Cited by 128
“These findings suggest that cognitive functioning should also be affected in healthy adults, but standard neuropsychological tests have provided only mixed evidence for changes in cognition associated with ApoE- 4 (e.g., Bondi et al., 1999; B. J. Small et al., 2000; Yaffe et al., 1997).”
InfluentialBartzokis, G., Lu, P. H., Geschwind, D. H., Edwards, N., Mintz, J., & Cummings, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.63 · Cited by 128
Self-citationA review of multivariate analyses in imaging genetics
Liu, J., & Calhoun, V. D. (2014) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2014.00029 · Cited by 146
3D texture analysis on MRI images of Alzheimer’s disease
Zhang, J., Yu, C., Jiang, G., Liu, W., & Tong, L. (2011) · Brain Imaging and Behavior · doi:10.1007/s11682-011-9142-3 · Cited by 141
“…structural atrophy rate measured by longitudinal MRI scans and glucose metabolism changes obtained with serial positron emission tomography (PET) (Drzezga et al. 2003; Du et al. 2003; Fox and Freeborough 1997; Fox et al. 1999, 2000; Minoshima et al. 1997; Silverman et al. 2001; Small et al. 2000).”
MethodInfluentialMapping the Alzheimer’s Brain with Connectomics
Xie, T., & He, Y. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00077 · Cited by 127
Silverman, D. H. S., Gambhir, S. S., Huang, H.-W. C., Schwimmer, J., Kim, S., Small, G. W., Chodosh, J., Czernin, J. G., & Phelps, M. E. (2002) · PubMed · Cited by 143
Self-citationExpression of β-Amyloid Induced Age-Dependent Presynaptic and Axonal Changes in Drosophila
Zhao, X.-L., Wang, W.-A., Tan, J.-X., Huang, J.-K., Zhang, X., Zhang, B.-Z., Wang, Y.-H., YangCheng, H.-Y., Zhu, H.-L., Sun, X.-J., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3699-09.2010 · Cited by 130
“, 2009) and the metabolic decline (glucoses utility and oxygen consumption) in nondemented individuals genetically at risk for AD (Bookheimer et al., 2000; Small et al., 2000).”
BackgroundRETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128
“Residual plots were examined for possible violations in the assumptions of linear regression.”
BackgroundRetractedMitochondrial dysfunction and Alzheimer's disease
Maruszak, A., & Żekanowski, C. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.004 · Cited by 140
Stieler, J. T., Bullmann, T., Kohl, F., Tøien, Ø., Brückner, M. K., Härtig, W., Barnes, B. M., & Arendt, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014530 · Cited by 116
Insulin Resistance, Affective Disorders, and Alzheimer's Disease: Review and Hypothesis
Rasgon, N., & Jarvik, L. (2004) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/59.2.m178 · Cited by 120
“In addition, APOE-4 has been associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in AD ( 79 ,80).”
BackgroundSelf-citationFonseca, A. C. R. G., Ferreiro, E. B., Oliveira, C. R., Cardoso, S. M., & Pereira, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.007 · Cited by 122
“Second, combined evidences from neuroimaging and neuropathological studies show that signs of vascular pathology develop early in AD and occur before the disease becomes symptomatic [5, 6].”
BackgroundConcurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting
Li, X., Lu, F., Wang, J., & Gong, C. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04735.x · Cited by 116
“This impairment occurs prior to the onset of AD, and it worsens while the disease progresses (de Leon et al., 1983; Smith et al., 1992; Hoyer, 1993; Small et al., 2000; Reiman et al., 2001; Alexander et al., 2002; Hoyer, 2004).”
BackgroundEstrogen use and brain metabolic change in postmenopausal women
Rasgon, N., Silverman, D. H. S., Siddarth, P., Miller, K. J., Ercoli, L. M., Elman, S., Lavretsky, H., Huang, S. C., Phelps, M. E., & Small, G. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.003 · Cited by 126
“lateral temporal and posterior cingulate) exhibit the greatest magnitude of metabolic decline after 2 years in middle-aged and older persons at risk for AD [33,34].”
BackgroundSelf-citationPlaque and tangle imaging and cognition in normal aging and Alzheimer's disease
Braskie, M. N., Klunder, A. D., Hayashi, K. M., Protas, H., Kepe, V., Miller, K. J., Huang, S.-C., Barrio, J. R., Ercoli, L. M., Siddarth, P., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.012 · Cited by 114
Self-citationEnhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years
Mondadori, C. R. A., Buchmann, A., Mustovic, H., Schmidt, C. F., Boesiger, P., Nitsch, R. M., Hock, C., Streffer, J., & Henke, K. (2006) · Brain · doi:10.1093/brain/awl266 · Cited by 120
“Examinations with fluorodeoxyglucose positron emission tomography (PET) in cognitively intact carriers of the apolipoprotein E «4 allele (APOE4), the major genetic risk factor for sporadic Alzheimer’s disease (SAD; Small et al., 2000; de Leon et al., 2001; Reiman et al., 2004), revealed a reduced glucose metabolism in…”
BackgroundMethodGenetics of human prefrontal function
Winterer, G., & Goldman, D. A. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00205-4 · Cited by 133
Brain aging and Alzheimer's disease; use it or lose it
Swaab, D. F., Dubelaar, E. J. G., Hofman, M. A., Scherder, E., Someren, E. J. W. V., & Verwer, R. W. H. (2002) · Progress in brain research · doi:10.1016/s0079-6123(02)38086-5 · Cited by 124
Liraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118
“Recent studies suggest that in addition to the effects of apoE4 on brains of the aged population [97,98], it also affects the brains of apparently healthy younger apoE4 carriers [8,31,46,99-101].”
BackgroundCerebral glucose metabolism in patients with AD and different APOE genotypes
Drzezga, A., Riemenschneider, M., Strassner, B., Grimmer, T., Peller, M., Knoll, A., Wagenpfeil, S., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · Neurology · doi:10.1212/01.wnl.0000148478.39691.d3 · Cited by 116
Evidence for an association between KIBRA and late-onset Alzheimer's disease
Corneveaux, J. J., Liang, W. S., Reiman, E. M., Webster, J. A., Myers, A. J., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Craig, D. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.014 · Cited by 114
Neuroimaging as a marker of the onset and progression of Alzheimer's disease
Masdeu, J. C., Zubieta, J. L., & Arbizu, J. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.001 · Cited by 124
“026) between memory loss and baseline parietal metabolism in the group of people with ApoE4, but not in the group without this allele [80].”
BackgroundAgdeppa, E. D., Kepe, V., Liu, J., Small, G. W., Huang, S., Petrič, A., Satyamurthy, N., & Barrio, J. R. (2003) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2003.09.010 · Cited by 121
Caselli, R. J., & Reiman, E. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129026 · Cited by 109
“1), precuneus, parietal, temporal, and frontal regions, in people with one or two copies of the APOE ε4 allele, in Down syndrome patients and mutation carriers at risk for autosomal dominant earlyonset AD, and in those with higher rates of subsequent cognitive decline [55–67].”
Background
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.